INTRODUCTION
There has been a steadily growing interest in research on prescription drug misuse in the wake of the opioid epidemic 1 and rising concerns of misuse of other prescribed drugs, such as benzodiazepines. 2 Prescription drug misuse is the use of prescription medications outside the parameters of its prescribed use such as using in greater amounts, for prolonged periods of time, or for purposes other than prescribed. Prescription opioid misuse, in particular, has been declared a public health emergency in the United States. While opioid prescription rates have decreased steadily over the past several years, 3 deaths involving prescription opioids have more than quadrupled between 1999 and 2015 based on analyses of the National Vital Statistics multiple cause-of-death mortality files. 4, 5 Data from the National Survey of Drug Use and Health (NSDUH) have evidenced that drug overdose death rates involving prescription opioids increased among adults from 4.5 per 100,000 (95%CI, 4.42-4.61) in 2003 to 7.8 2003-7.8 per 100,000 (95%CI, 7.64-7.89) in 2013 (absolute difference, 3.3; 95%CI, 3.09-3.41). 6 Use and abuse of recreational substances-drugs used for their psychoactive effects without medical justification (eg, alcohol, tobacco, marijuana, cocaine, etc.)-has been correlated to prescription opioid use in adolescent 7 and adult samples. 8, 9 However, patterns of past month prescription opioid misuse and recreational substance use has not been well characterized or described in relation to sociodemographic characteristics or social and behavioral health indicators.
Han et al. 9 examined rates and correlates of prescription drug misuse and abuse using the 2015 National Survey on Drug Use and Health (NSDUH), a nationally representative cross-sectional survey. The authors noted, among other findings, a high percentage of prescription opioid misusers also reported previous or current substance use disorders in the past year. However, the use of past year responses makes it difficult to determine whether or not prescription and recreational drugs are used in a comorbid fashion or if users transitioned from opioids to other substances or vice versa. This has important implications for public health research, policy development, and clinical intervention.
Combining prescription opioids with recreational drugs, such as alcohol, can interact to produce a harmful and potentially lethal chemical effects for the user, 10, 11 and increase the risk for overdose-though previous research shows concurrent prescription opioid and illicit drug users perceive risk as low. 12 The combination of prescription opioids and benzodiazepines has been a primary area of concern given their potential for harm, 13, 14 but less attention has focused on prescription opioid and comorbid use of recreational substances despite the prevalence of recreational drug use of substances-such as alcohol, tobacco, and marijuana-is higher than prescription drug misuse. 15 Misuse of prescription opioids and recreational substance use behaviors is consistent with research indicating that prescription drug misuse is associated with an increased risk of mental health problems, including substance use disorders. 9, 16, 17 Prescription opioid misuse, specifically, has been assessed in relation to major depression 16 and suicidal ideation. 18 While these studies adjusted for lifetime or past year substance use and substance use disorder, they did not examine the comorbid use of prescription opioids and other substances. Similarly, there is little evidence to the knowledge of the authors regarding current comorbid use of prescription opioids and recreational substances and its relation to social and behavioral problems such as risky sexual practices and outcomes, stealing property, or engaging in illicit drug activity such as selling drugs. Among substance users entering treatment, national data suggests that approximately 41% report using both drugs and alcohol 19 suggesting that individuals in need of substance use treatment are engaged in polydrug use-the use of two or more drugs within a specified time frame. 20 The aim of the present investigation was to: (i) identify the profiles of past month prescription opioid misuse in the context of other substance use behavior; (ii) describe demographic correlates of opioid misuse and comorbid substance use types; (iii) explore the relationship between opioid and comorbid substance use with other social and behavioral health indicators; and (iv) examine differences in the source of prescription pain medication.
METHODS

Study Population
Data were analyzed from the 2016 NSDUH a yearly crosssectional data collection effort on the use of legal and illegal substances, mental health, and other correlates. The study is described in-depth elsewhere. 21 Briefly, a multistage area probability sample (N ¼ 67,942) was conducted for each of the 50 states and the District of Columbia to represent the U.S. male and female civilian non-institutionalized population aged !12 years. Data were collected from respondents by computer-assisted personal interviewing conducted by an interviewer and audio computer-assisted self-interviewing. NSDUH data collection was approved by the institutional review board at RTI International. Verbal informed consent was received from each study participant. Data for the current analysis (2016 survey) were extracted from the public data portal (www.datafiles.samhsa.gov/), and is the most recently available data. In 2016, the weighted response rate for completed household interviews was 68.4% with an overall response rate of 53.3% for people ages 12 and older. Multiple imputation was used to account for missing data. 21 
Measures
Prescription Opioid Misuse Profiles
To classify prescription opioid misuse types, the sample was first limited to only respondents who reported past month recreational substance use (alcohol, tobacco, marijuana, hard drugs) or prescription opioid misuse (N ¼ 26,033). We then create profiles of prescription opioid misuse as respondents reporting: (i) prescription opioid misuse only; (ii) prescription opioid misuse and past month alcohol or cigarette use; (iii) prescription opioid misuse and past month use of one illicit drug (marijuana, cocaine, crack, heroin, LSD, PCP, ecstasy, ketamine, DMT/AMT/FOXY, salvia, inhalants, methamphetamine); (iv) prescription opioid misuse and use of more than one recreational drug in the past month; and (v) past month recreational drug users reporting no prescription opioid misuse. The recreational drug users reporting no prescription opioid misuse group was the referent category for all analyses. Prescription opioid and comorbid substance use profiles were examined in the past month rather than past year.
Sociodemographic Covariates
Gender was coded 0 ¼ female and 1 ¼ male. Age was categorized as 12-17 years old, 18-25 years old, and 26 years and older. Race/ethnicity was categorized as Non-Hispanic White, Non-Hispanic African/American or Black, Hispanic, Asian, Native American or Alaskan Native, Hawaiian or Pacific Islander, and two or more. Due to small cell sizes final analyses collapsed ethnic groups into Non-Hispanic White, Non-Hispanic African/American or Black, Hispanic, other, and two or more. Annual income was grouped as less than $20,000, $20,000-$39,999, $40,000-$74,999, and $75,000 or more.
Social and Behavioral Health Indicators
Items asked about past year major depressive episode, stealing of property worth $50 or more, selling illegal drugs, having any sexually transmitted disease, suicidal ideation (among adult respondents), and perceived treatment need for alcohol or drug use problems. Two items (selling illegal drugs and major depressive episode) were assessed with separate items for adolescents and adults but were coded consistently as yes/no indicators. Items were dichotomized as yes (1) and no (0) responses.
Source of Pain Medication
One item assessed source of pain medications among prescription opioid misusers. Possible responses included one doctor; more than one doctor; stealing from a doctor's office clinic, hospital or pharmacy; getting from a friend or relative (for free, through purchase, or by stealing); buying from a dealer or stranger, or some other way.
Sample weights were applied to yield nationally representative estimates which are represented as percentages in this report. First, prevalence estimates were derived and bivariate associations were assessed across the profiles of prescriptions opioid misusers with covariates. A multinomial logistic regression model was used to examine the relationships between demographic correlates of prescription opioid misuse profiles. Separate logistic regression models were used to assess the relationship between prescription opioid misuse profiles with other self-reported outcomes (stealing property, selling drugs, STD infection, suicidal ideation, and perceived substance use treatment need). Analyses were conducted with Stata version 14.0 (StataCorp, 2015) using the SVY command to account for the complex sample design and sampling weights of NSDUH data. NSDUH suppression rules were followed in accordance with the Methodological Summary and Definitions guidelines. 21 Results are presented as Relative Risk Ratios (RRR) or Adjusted Odds Ratios (AOR) with 95% confidence intervals (95%CI).
RESULTS
Based on 26,033 respondents reporting past 30-day substance use, it was estimated that 2.5% (95%CI ¼ 2.2-2.7%) of this population are past month prescription opioid misusers. The majority reported prescription opioid and polydrug use (.67%, 95%CI ¼ .56-.79%) followed by prescription opioid only use (.63%, 95%CI ¼ .51-.77%), prescription opioid and alcohol use (.48%, 95%CI ¼ .34-.61%), prescription opioid and marijuana use (.44%, 95%CI ¼ .35-.53%), prescription opioid and cigarette use (.19%, 95%CI ¼ .11-.27%), and prescription opioid and hard drug use (.03%, 95%CI ¼ .01-.06%). The cigarettes and alcohol categories were combined into a "prescription opioid and licit drug" category while the marijuana and hard drug categories were combined into a "prescription opioid and illicit drug" category. The analytic sample was 51.5% female, predominantly non-Hispanic White (63.4%), age 26 or older (77.9%), with 37.5% reporting an annual income of $75,000 or more (Table 1) .
Compared to past month substance users who did not report prescription opioid use, the risk of reporting prescription opioid use only was higher for participants ages 12-17 (RRR ¼ 5.17, 95%CI ¼ 3.38-7.90) and those with an annual income of $20,000 or less (RRR ¼ 2.47, 95%CI ¼ 1.24-4.92). Males were 1.63 times more likely than females to report prescription opioid and use of one illicit drug (95%CI ¼ 1.09-2.44) and 1.46 times more likely to report prescription opioid and polydrug use (95%CI ¼ 1.04-2.04). Additionally, compared to those with an annual income between $40,000-$74,999 the risk of prescription opioid and polydrug use was higher for those reporting an annual income of $20,000 or less (RRR ¼ 2.38, 95%CI ¼ 1. 35-4.19 ) and lower for those reporting an income of $75,000 or more (RRR ¼ .42, 95% CI ¼ .24-.75) ( Table 2) .
Social and behavioral health indicators were examined in relation to past month opioid use profiles after adjusting for gender, age, race/ethnicity, and income (Table 3 ). Past year major depressive episode was associated with an increased risk of all past month prescription opioid use profiles relative to past month substance use that did not involve prescription opioids CI ¼ 11.27-24.89) was also highest among past month prescription opioid and polydrug users. All past month prescription opioid use profiles were associated with an increased risk of past year major depressive episode.
Sources of pain medication was examined for prescription opioid only users compared to prescription opioid and comorbid substance users (Figure 1 ). Getting pain medication from a friend or relative for free was the primary source for both prescription opioid only users (43.9%) and prescription opioid and comorbid substance users (33.2%). A chi-square test of independence was performed to examine the relation between type of prescription opioid user (opioid only or opioid and comorbid substance use) and different sources of pain medication. There was a significant relationship between type of prescription opioid user and buying from a friend or relative (x 2 (1,821) ¼ 21.51, p < .0001) and buying from a drug dealer or other stranger (x 2 (1,821) ¼ 10.14, p < .0015).
DISCUSSION
High rates of past month prescription opioid and comorbid substance use was observed in the 2016 NSDUH sample. This is especially concerning given the potential health risks that combining substances poses to the user. Sociodemographic variables were examined as correlates of past month prescription opioid and comorbid substance use profiles. Notably, males and younger respondents (adolescents aged 12-17 and young adults aged 18-25) were more likely to report prescription opioid and illicit, or polydrug use. Our findings are limited to discussing comorbid, and not combined, profiles of use. Individuals reporting past 30-day comorbid prescription opioid misuse and recreational substance use reflect one of three types of comorbid substance users: simultaneous users-who consume multiple drugs in the same session motivated by the enhanced high achieved by combining multiple psychoactive substances, 22 concurrent users who report the use of multiple drugs at different times motivated by availability and substitution practices, 20 and transitional users who move from one drug to another (eg, prescription opioid to heroin) or one route of administration to another (eg, non-injection to injection) due to financial reasons or heightened intensity of the drug effect. 23 Due to the nature of the NSDUH data, it was not possible to conduct an event level analysis of prescription opioid and comorbid substance use behaviors. Nevertheless, the risks from combining substances is important to consider. Combining prescription opioids with some substances, such as alcohol can be lethal, 10 but there is no evidence of harm due to the combined use of prescription opioids with cigarette use, for example. Timeline Followback assessment, a retrospective calendar-based measure of substance use, is a reliable method for assessing recent daily use of alcohol 24 and other substances. 25 Incorporating these strategies into national survey inventories will strengthen the ability of researchers to determine event level patterns of comorbid prescription opioid misuse and recreational substance use and better understand the physical, psychological, and behavioral consequences of disparate use patterns.
Prescription opioid and comorbid substance use was a significant correlate of several past year social and behavioral health indicators when compared to substance users with no self-reported prescription opioid use. Relative to prescription opioid only users, polydrug users reporting prescription opioid use had an increase in the odds of past-year stealing, selling illegal drugs, having an STD, suicidal ideation or needing substance use treatment. NSDUH data indicate that the primary reason for misuse of prescription pain killers is pain (62.6%). 26 Individuals with existing physical, behavioral, and mental health problems may be at a higher risk of prescription opioid misuse due to associated pain related symptoms or as a coping mechanism for psychological and behavioral problems. 17 Without a biological test of pain assessment, patients are left to self-report their pain levels and those experiencing other behavioral of mental health problems may report pain as a symptom needing treatment. Alternatively, there is a possibility that prescription opioid misusers have an underlying, comorbid personality disorder that heightens the risk for prescription drug misuse and abuse, 27 and their propensity for experiencing adverse behaviors and related outcomes. 28 Individuals misusing or abusing multiple substances might be especially vulnerable to other social or behavioral 
Opioid only
Opioid RRR, relative risk ratio; 95%CI, 95% confidence interval; MDE, major depressive episode. Alcohol or cigarette use collapsed into single category of "Opioid þ licit drug" and marijuana or hard drug use collapsed into single category of "Opioid þ illicit drug."
problems. Davis 16 proposed that the relationship between mental illness and prescription opioid misuse is likely bidirectional and this may be true with suicidal ideation as well. Kuramoto 18 found that individuals who no longer reported using prescription opioids were more likely to report suicidal ideation. More longitudinal research is needed to disentangle these relationships. While screening for depression is recommended before prescribing prescription opioids for pain management, screening is strongly encouraged when physicians suspect or are aware of other substance use behaviors.
National data suggests that nearly half of all individuals who misuse prescription opioids procure the medication from a friend or relative for free, by stealing, or paying. 29 The same study suggested that family and friends serve as a primary source for securing prescription pain medication. However, one report 30 demonstrated that source of prescription opioids varied by frequency of past-year nonmedical use. The results indicated that while this was true for the lowest frequency users (1-29 days), the highest frequency users (200-365 days) were more likely than those with the lowest frequency of use to obtain opioids from a physician's prescription or from a drug dealer. In light of these findings, and given the current widespread opioid abuse problem, physicians should consider encouraging patients to dispose of unused opioid medications especially when other household members may be at risk for misuse if they are able to access the drugs. Similar to high frequency opioid misusers, 30 prescription opioid and comorbid substance users were more likely to buy prescription opioids from a friend or relative which could be a sign of heightened drug seeking behavior and requires further investigation. Drug seeking behavior refers to a wide range of behaviors including pressuring doctors for drugs, forging prescriptions, or obtaining the drugs from illicit sources that is frequently indicative of increasing dependence. This data also suggests that prescription opioid users engaged in other substance use behaviors are more likely to purchase opioids from strangers or drug dealers. This finding is startling as these individuals can be exposed to other risks associated with purchasing illicit drugs-such as unintentionally consuming laced drugs. Future research should consider if and how frequency of prescription opioid misuse contributes to the health outcomes of comorbid use observed in this analysis.
This analysis should be considered in light of several limitations. First, due to the cross-sectional nature of the data we cannot assume causal relationships between the variables under study. We also observed variables with different time intervals (past month, past year) further limiting our ability to derive temporal sequencing of events. However, the research design and sample weights improve the confidence that the relationships observed in this analysis are representative of substance users in the United States. Second, the design of the survey does not allow us to examine event level substance use or distinguish between simultaneous and concurrent opioid and drug users. Past month use was examined and it is possible that some users engaged in comorbid prescription opioid and substance use previously but were not captured in the present analysis. Moreover, we included past month cigarette use but not general tobacco use due to the high overlap in use of multiple tobacco products among cigarette smokers. Replication analyses using any past month tobacco use produced near identical findings. Third, this sample was limited to noninstitutionalized individuals and limits our generalizability when discussing subpopulations including, but not limited to, active duty military personnel and prisoners. These populations warrant further exploration given their risk for substance use and misuse relative to the general population 31, 32 and need for specific health care issues. Fourth, we categorized licit (cigarettes and alcohol) and illicit (marijuana, cocaine, etc.) substances based on the national legal status of the substances and their availability for purchase and possession. However, youth cannot purchase licit drugs due to age restrictions, but this population would have increased access to these products through peer networks or availability in their households. Finally, responses were self-reported and susceptible to recall bias which may affect the validity of the findings.
Public health and clinical experts continue to debate the best practices for opioid prescribing and pain management through policy or system level intervention, 33 abuse deterrent formulas, 34 or patient level interventions such as developing addiction vaccines 35 or exploring alternative treatments for chronic pain management. The findings of this study suggest that prescription opioid misuse is likely a part of a larger set of physical, psychological, and behavioral problems facing patients at risk of an opioid use disorder or overdose. Addressing the entire clinical picture, including co-occurring substance use and other medical issues or associated health behaviors, will be necessary to end the prescription opioid epidemic and prevent another one from unfurling in the future.
